Skip to content

The efficacy of EMDR in youngsters with autism

The efficacy of EMDR in youngsters with autism - Eye-Catcher

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON45375
Enrollment
20
Registered
2017-06-13
Start date
2017-11-01
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Autism spectrum disorder

Interventions

Ten weekly EMDR sessions.

Sponsors

Karakter, expertisecentrum voor kinder- en jeugdpsychiatrie
Lead Sponsor

Eligibility

Age
12 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Diagnosed with ASD (with or without comorbid psychiatric disorders, except PTSD and anxiety disorders) • Full-scale IQ of 80 or more • 12-21 years of age • Able to understand and speak Dutch

Exclusion criteria

Exclusion criteria: • Youngsters exposed to other treatments than medication on a stable dosage • Presence of PTSD or other comorbid psychiatric disorders that require immediate treatment

Design outcomes

Primary

MeasureTime frame
The main endpoint of the study are autism symptoms, which will be assessed using the Social Responsiveness Scale (SRS-A) and the Autism Diagnostic Observation Schedule (ADOS 2). The SRS-A will be administered prior, during and after treatment. The ADOS 2 will be administered prior to treatment and after treatment completion. In addition, we will also administer the Trauma Symptom Investigation Form in Autism Spectrum Disorders (TIF-ASD) questionnaire prior to, during, and after treatment.

Secondary

MeasureTime frame
To answer more fundamental questions concerning the working mechanism of EMDR in ASD, other secondary outcome measures (i.e. Clinical Global Impression Scales (CGI), Perceived Stress Scale-10 (PSS-10) en de Alloway Working Memory Assessment (AWMA-2)) will be included.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)